STOCK TITAN

Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

On February 10, 2021, Biophytis announced a temporary halt in trading of its shares on Euronext Growth as it prepares for its initial public offering of American Depositary Shares (ADSs) on the Nasdaq Capital Market under the ticker symbol BPTS. The halt is in effect from 9 a.m. CET and is expected to last until approximately 4 p.m. CET, when Euronext trading will resume. The IPO aims to gain capital for developing therapeutics focused on age-related diseases, including severe respiratory failure linked to COVID-19.

Positive
  • Preparation for IPO on Nasdaq could enhance market visibility and capital influx.
  • Focused on therapeutics for severe respiratory failure, addressing critical health challenges.
Negative
  • Trading halt may create uncertainty among investors.
  • Forward-looking statements highlight underlying risks related to product development and regulatory approvals.

PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces today that trading of its ordinary shares and share warrants on Euronext Growth will be temporarily halted at the Company’s request from the opening of the market at 9 a.m. CET in the context of its initial public offering on the Nasdaq Capital Market in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company’s American Depositary Shares (ADSs) on the Nasdaq Capital Market.

This trading halt will remain effective until a new communication is released by the Company. Trading on the regulated market of Euronext Growth is expected to resume today, February 10, 2021, at approximately 4 p.m. (CET), which is the earliest time the ADSs are expected to begin trading on the Nasdaq Capital Market (10 a.m. (EST)) under the ticker symbol “BPTS”.

About Biophytis

Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19.

The company is based in Paris, France, and Cambridge, Massachusetts. The company's ordinary shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825).

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include certain statements regarding Biophytis’ proposed initial public offering as well as its business, including its prospects and product development. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, risks inherent in the development and/or commercialization of potential products, the outcome of its studies, uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under "Risk Factors" in Biophytis’ registration statement relating to the initial public offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

No communication or information relating to the ADS offering by Biophytis may be transmitted to the public in a country where there is a registration obligation or where an approval is required. The issuance of the securities of the Company may be subject to legal and regulatory restrictions in certain jurisdictions; none of Biophytis and the bank involved in the ADS offering assumes any liability in connection with the breach by any person of such restrictions.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council as supplemented by Commission Delegated Regulation (EU) 2019/980 (the “Prospectus Regulation”).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to any securities of Biophytis in any country. This press release is not an offer to the public, an offer to subscribe or designed to solicit interest for purposes of an offer to the public in any jurisdiction, including France.

No action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member States of the European Economic Area, including France (the “Member States”). Therefore, such securities may not be and shall not be offered in any Member State other than in accordance with the exemptions of Article 1(4) of the Prospectus Regulation or, otherwise, in cases not requiring the publication by Biophytis of a prospectus under Article 3 of the Prospectus Regulation and/or the applicable regulations in such Member State.

This press release and the information it contains are being distributed to and are only intended for persons who are (x) outside the United Kingdom or (y) in the United Kingdom who are qualified investors (as defined in the Prospectus Regulation as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) and are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies”, “unincorporated associations”, etc.) or (iii) other persons to whom an invitation or inducement to participate in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (y)(i), (y)(ii) and (y)(iii) together being referred to as “Relevant Persons”). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this press release relates will only be engaged with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this press release or any of its contents.

This press release and the information contained therein does not, and will not, constitute an offer of securities for sale, nor the solicitation of an offer to purchase, securities in the United States or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”). The securities of Biophytis will be registered under the Securities Act, and Biophytis intends to conduct a public offering in the United States.

Biophytis Investor Relations ContactMedia Contact
Evelyne Nguyen – CFOLifeSci Advisors
Evelyne.nguyen@biophytis.comSophie Beaumont
 sophie@lifesciadvisors.com
 Mobile: +33 (0)6 27 74 74 49
Investor Relations 
LifeSci Advisors, LLC  
Sandya von der Weid 
E: svonderweid@lifesciadvisors.com 
T: +41 78 680 05 38 



FAQ

What is the purpose of Biophytis' trading halt on February 10, 2021?

The trading halt allows Biophytis to confirm allocations to investors for its IPO on the Nasdaq.

When will Biophytis resume trading on Euronext Growth?

Trading is expected to resume around 4 p.m. CET on February 10, 2021.

Under what symbol will Biophytis’ American Depositary Shares trade on Nasdaq?

The ADSs will trade under the ticker symbol BPTS on the Nasdaq.

What type of diseases is Biophytis focusing on?

Biophytis focuses on therapeutics for age-related diseases, including severe respiratory failure from COVID-19.

Biophytis SA American Depositary Share (0.01 Euro)

NASDAQ:BPTS

BPTS Rankings

BPTS Latest News

BPTS Stock Data

2.36M
1.40B
0.05%
3.22%
Biotechnology
Healthcare
Link
United States of America
Paris